The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
D-type cyclins (D1, D2 and D3) and their associated cyclin-dependent kinases (CDK4 and CDK6) are components of the core cell cycle machinery that drives cell proliferation. Inhibitors of CDK4 and CDK6 are currently being tested in clinical trials for patients with several cancer types, with promising results. Here, using human cancer cells and patient-derived xenografts in mice, we show that the cyclin D3-CDK6 kinase phosphorylates and inhibits the catalytic activity of two key enzymes in the glycolytic pathway, 6-phosphofructokinase and pyruvate kinase M2. This re-directs the glycolytic intermediates into the pentose phosphate (PPP) and serine pathways. Inhibition of cyclin D3-CDK6 in tumour cells reduces flow through the PPP and serine pathways, thereby depleting the antioxidants NADPH and glutathione. This, in turn, increases the levels of reactive oxygen species and causes apoptosis of tumour cells. The pro-survival function of cyclin D-associated kinase operates in tumours expressing high levels of cyclin D3-CDK6 complexes. We propose that measuring the levels of cyclin D3-CDK6 in human cancers might help to identify tumour subsets that undergo cell death and tumour regression upon inhibition of CDK4 and CDK6. Cyclin D3-CDK6, through its ability to link cell cycle and cell metabolism, represents a particularly powerful oncoprotein that affects cancer cells at several levels, and this property can be exploited for anti-cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The cyclin D3/CDK6 kinase complex can phosphorylate 6-phosphofructokinase and pyruvate kinase M2 (Wang et al., 2017).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Wang et al., 2017
In the citing paper
“This has the effect of pushing glycolytic intermediates into the pentose phosphate and serine pathways, and inhibition of CDK6 (through treatment with palbociclib, ribociclib, or knockdown of CDK6) depletes the antioxidants NADPH and glutathione, increasing ROS and apoptosis.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Wang et al., 2017
In the citing paper
“These cells express very low levels of cyclin D1, cyclin D2, and CDK4, and the proliferative decision is dependent upon cyclin D3 and CDK6 (Wang et al., 2017; Wolowiec et al., 1996).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Wang et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eng, J. K., McCormack, A. L., & Yates, J. R. (1994) · Journal of the American Society for Mass Spectrometry · doi:10.1016/1044-0305(94)80016-2 · Cited by 6,484
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Elias, J. E., & Gygi, S. P. (2007) · Nature Methods · doi:10.1038/nmeth1019 · Cited by 3,925
Self-citationThe M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820
A tissue-specific atlas of mouse protein phosphorylation and expression
Huttlin, E. L., Jedrychowski, M. P., Elias, J. E., Goswami, T., Rad, R., Beausoleil, S. A., Villén, J., Haas, W., Sowa, M. E., & Gygi, S. P. (2010) · Cell · doi:10.1016/j.cell.2010.12.001 · Cited by 1,778
Self-citationMalumbres, M. (2014) · Genome Biology · doi:10.1186/gb4184 · Cited by 1,654
Beausoleil, S. A., Villén, J., Gerber, S. A., Rush, J., & Gygi, S. P. (2006) · Nature Biotechnology · doi:10.1038/nbt1240 · Cited by 1,577
Self-citationGao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393
Self-citationAnastasiou, D., Poulogiannis, G., Asara, J. M., Boxer, M. B., Jiang, J.-K., Shen, M., Bellinger, G., Sasaki, A. T., Locasale, J. W., Auld, D. S., et al. (2011) · Science · doi:10.1126/science.1211485 · Cited by 1,190
Quantitative flux analysis reveals folate-dependent NADPH production
Fan, J., Ye, J., Kamphorst, J. J., Shlomi, T., Thompson, C. B., & Rabinowitz, J. D. (2014) · Nature · doi:10.1038/nature13236 · Cited by 1,114
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells
Mazurek, S. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.02.005 · Cited by 694
Phosphofructokinase 1 Glycosylation Regulates Cell Growth and Metabolism
Yi, W., Clark, P. M., Mason, D. E., Keenan, M. C., Hill, C., Goddard, W. A., Peters, E. C., Driggers, E. M., & Hsieh-Wilson, L. C. (2012) · Science · doi:10.1126/science.1222278 · Cited by 676
Serine is a natural ligand and allosteric activator of pyruvate kinase M2
Chaneton, B., Hillmann, P., Zheng, L., Martin, A. C. L., Maddocks, O. D. K., Chokkathukalam, A., Coyle, J. E., Jankevics, A., Holding, F. P., Vousden, K. H., et al. (2012) · Nature · doi:10.1038/nature11540 · Cited by 661
Elementary metabolite units (EMU): A novel framework for modeling isotopic distributions
Antoniewicz, M. R., Kelleher, J. K., & Stephanopoulos, G. (2007) · Metabolic Engineering · doi:10.1016/j.ymben.2006.09.001 · Cited by 538
Cyclins and cdks in development and cancer: a perspective
Deshpande, A., Sicinski, P., & Hinds, P. W. (2005) · Oncogene · doi:10.1038/sj.onc.1208618 · Cited by 464
Determination of confidence intervals of metabolic fluxes estimated from stable isotope measurements
Antoniewicz, M. R., Kelleher, J. K., & Stephanopoulos, G. (2006) · Metabolic Engineering · doi:10.1016/j.ymben.2006.01.004 · Cited by 449
Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
Dean, J. L., Thangavel, C., McClendon, A. K., Reed, C. A., & Knudsen, E. S. (2010) · Oncogene · doi:10.1038/onc.2010.154 · Cited by 393
The molecular determinants of de novo nucleotide biosynthesis in cancer cells
Tong, X., Zhao, F., & Thompson, C. B. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.01.002 · Cited by 351
The Requirement for Cyclin D Function in Tumor Maintenance
Choi, Y. J., Li, X., Hydbring, P., Sanda, T., Stefano, J., Christie, A. L., Signoretti, S., Look, A. T., Kung, A. L., von Boehmer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.015 · Cited by 342
Quantifying Reductive Carboxylation Flux of Glutamine to Lipid in a Brown Adipocyte Cell Line
Yoo, H., Antoniewicz, M. R., Stephanopoulos, G., & Kelleher, J. K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706494200 · Cited by 301
An elementary metabolite unit (EMU) based method of isotopically nonstationary flux analysis
Young, J. D., Walther, J. L., Antoniewicz, M. R., Yoo, H., & Stephanopoulos, G. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21632 · Cited by 255
Cetica, P., Pintos, L., Dalvit, G., & Beconi, M. (2002) · Reproduction · doi:10.1530/rep.0.1240675 · Cited by 229
Dean, J. L., McClendon, A. K., Hickey, T. E., Butler, L. M., Tilley, W. D., Witkiewicz, A. K., & Knudsen, E. S. (2012) · Cell Cycle · doi:10.4161/cc.21195 · Cited by 226
Therapeutic Targeting of the Cyclin D3:CDK4/6 Complex in T Cell Leukemia
Sawai, C. M., Freund, J., Oh, P., Ndiaye-Lobry, D., Bretz, J. C., Strikoudis, A., Genesca, L., Trimarchi, T., Kelliher, M. A., Clark, M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.016 · Cited by 183
[11] Phosphofructokinases from Escherichia coli
Kotlarz, D., & BUC, H. C. (1982) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(82)90107-0 · Cited by 110
Loss of RBF1 changes glutamine catabolism
Nicolay, B. N., Gameiro, P. A., Tschöp, K., Korenjak, M., Heilmann, A. M., Asara, J. M., Stephanopoulos, G., Iliopoulos, O., & Dyson, N. J. (2013) · Genes & Development · doi:10.1101/gad.206227.112 · Cited by 88
Self-citationMarin‐Valencia, I., Cho, S. K., Rakheja, D., Hatanpaa, K. J., Kapur, P., Mashimo, T., Jindal, A., Vemireddy, V., Good, L. B., Raisanen, J., et al. (2012) · NMR in Biomedicine · doi:10.1002/nbm.2787 · Cited by 79
Structure and allosteric regulation of eukaryotic 6-phosphofructokinases
Schöneberg, T., Kloos, M., Brüser, A., Kirchberger, J., & Sträter, N. (2013) · bchm · doi:10.1515/hsz-2013-0130 · Cited by 70
Boada, J., Roig, T., Perez, X., Gamez, A., Bartrons, R., Cascante, M., & Bermúdez, J. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01950-5 · Cited by 61
Divita, G., Goody, R. S., Gautheron, D. C., & Pietro, A. D. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38635-1 · Cited by 60
Phong, W. Y., Lin, W., Rao, S. P. S., Dick, T., Alonso, S., & Pethe, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056037 · Cited by 56
Banaszak, K., Mechin, I., Obmolova, G., Oldham, M. L., Chang, S. H., Ruíz, T., Radermacher, M., Kopperschläger, G., & Rypniewski, W. R. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.01.019 · Cited by 54
Vertommen, D., Bertrand, L., Sontag, B., Pietro, A. D., Louckx, M. P., Vidal, H., Hue, L., & Rider, M. H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.30.17875 · Cited by 40
Functional Linkage of Adenine Nucleotide Binding Sites in Mammalian Muscle 6-Phosphofructokinase
Brüser, A., Kirchberger, J., Kloos, M., Sträter, N., & Schöneberg, T. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.347153 · Cited by 29
Cited by
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013
Self-citationThe Complex Interplay between Antioxidants and ROS in Cancer
Harris, I. S., & DeNicola, G. M. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.03.002 · Cited by 626
“Several studies have demonstrated the importance of NADPH generation and reductive capacity for tumorigenesis [74,75].”
BackgroundTargeting cell-cycle machinery in cancer
Suski, J. M., Braun, M., Strmiska, V., & Sicinski, P. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.010 · Cited by 564
Self-citationTargeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 531
Lactate and lactylation in cancer
Chen, J., Huang, Z., Chen, Y., Tian, H., Chai, P., Shen, Y., Yao, Y., Xu, S., Ge, S., & Jia, R. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02082-x · Cited by 477
“360,361 To add up, by intravenously administering primed [U-13 C]lactate (completely labeled with carbon-13 at three positions) and utilizing imaging mass spectro-metry (IMS), Bartman et al. mapped TCA cycle fl ux across various tumor models.”
Metadata
- Authors
- Wang, H., Nicolay, B. N., Chick, J. M., Gao, X., Geng, Y., Ren, H., Gao, H., Yang, G., Williams, J. A., Suski, J. M., Keibler, M. A., Sicinska, E., Gerdemann, U., Haining, W. N., Roberts, T. M., Polyak, K., Gygi, S. P., Dyson, N. J., & Sicinski, P.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Massachusetts Institute of Technology (US)
- Dana-Farber Cancer Institute (US)
- Broad Institute (US)
- ORCID
- Venue
- Nature
- Published
- 2017-06
- Volume
- 546
- Issue
- 7658
- Pages
- 426-430
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5516959
- OpenAlex
- W2624626767
- Cited by
- 347
- References
- 37
- Citations by year
- 2026: 20 · 2025: 31 · 2024: 29 · 2023: 43 · 2022: 41 · 2021: 45 · 2020: 61 · 2019: 32 · 2018: 30 · 2017: 15
- FWCI
- 12.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- The Novartis Repository (Novartis) (submittedVersion)
- Funders
- National Cancer Institute (R01CA190509, P50CA090381, F32CA165856, T32CA009361, R01CA202634, P01CA080111, R01CA163698, R01CA083688)
- National Institute of General Medical Sciences (R01GM067945)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- cyclin D3, CDK6, cyclin-dependent kinases, tumor cell survival, glycolysis, 6-phosphofructokinase, PKM2, pentose phosphate pathway, serine pathway, NADPH, glutathione, reactive oxygen species, oxidative stress, apoptosis, CDK4/6 inhibitors, RB1, patient selection
- MeSH terms
- Aminopyridines, Animals, Cell Cycle, Cell Survival, Female, Glycolysis, Humans, Neoplasms, Pentose Phosphate Pathway, Phosphofructokinase-1, Phosphorylation, Purines, Pyruvate Kinase, Serine, Apoptosis, Reactive Oxygen Species, Oxidative Stress, Xenograft Model Antitumor Assays, Reactive Nitrogen Species, Cell Line, Tumor, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Cyclin D3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.